Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.

@article{Binnie1989DoubleblindCT,
  title={Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy.},
  author={C. D. Binnie and Ren{\'e} M Chr Debets and Martijn Engelsman and Jan Willem Meijer and H. Meinardi and Jan Overweg and A. W. Peck and A van Wieringen and Wai Cheung Yuen},
  journal={Epilepsy research},
  year={1989},
  volume={4 3},
  pages={222-9}
}
A double-blind, placebo-controlled trial is reported of lamotrigine as add-on treatment in therapy-resistant epilepsy. A within-patients serial design was used, with two 3-month treatment periods and an intervening 6-week washout/crossover period. An unblinded investigator adjusted lamotrigine dosage to achieve a plasma concentration within a previously predicted therapeutic range. All patients had therapy-resistant partial seizures, some in combination with other seizure types and were without… CONTINUE READING